Clinical Trials Logo

Clinical Trial Summary

The understanding of ARVC pathophysiology remains incomplete. Several clues indicate that disease progression is mediated through inflammation. The present study aim to document the feasibility of detecting the potential presence of intracardiac local inflammatory components in patients with ARVC.

Clinical Trial Description

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a heritable condition characterized by right ventricular (RV) dilatation/dysfunction and malignant ventricular arrhythmias. The understanding of ARVC pathophysiology remains incomplete. Several clues indicate that disease progression is mediated through inflammation. First, presence of subepicardial late gadolinium enhancement sharing the same characteristics as the ones found in myocarditis is common on cardiac magnetic resonance imaging (CMR). Second, clinical pathology findings of inflammatory infiltrates of mononuclear cells are frequent and correlate to the extent and severity of ARVC. Finally, from a biological standpoint, the exploratory study conducted by Campian et al. has shown an exaggerated humoral inflammatory response in peripheral blood whilst anti-desmoglein-2 antibodies (targeting a component of the desmosome) emerge as a sensitive and specific biomarker for ARVC. As specific treatments for ARVC are currently lacking, a better understanding of the humoral pathophysiology of the disease could unlock new therapeutic targets. We recently demonstrated that collecting local cardiomyocytes was feasible through irrigated ablation catheters in patients with ARVC. These steerable catheters may easily map the whole right ventricle and locate endocardial or epicardial scars. Aspiration of local blood or cellular material through the inner lumen of the catheter once pressed on the parietal wall may be an interesting technique for retrieving local inflammation markers. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05209776
Study type Interventional
Source University Hospital, Toulouse
Contact Philippe MAURY, MD
Phone 5 61 32 34 70
Status Recruiting
Phase N/A
Start date February 1, 2022
Completion date February 1, 2024

See also
  Status Clinical Trial Phase
Completed NCT00999947 - Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy N/A
Completed NCT00024505 - Multidisciplinary Study of Right Ventricular Dysplasia N/A
Completed NCT03177018 - DNA Analysis From Isolated Cardiomyocytes in the Molecular Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia N/A
Recruiting NCT00221832 - Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases N/A
Active, not recruiting NCT04257994 - Distribution of Cell-cell Junction Proteins in Arrhythmic Disorders
Not yet recruiting NCT03593317 - Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD Phase 2
Recruiting NCT05521451 - Clinical Cohort Study - TRUST
Recruiting NCT03049254 - Mayo AVC Registry and Biobank
Recruiting NCT04712136 - Healthy-related Quality of Life and Physical Activity of Children With Cardiac Malformations N/A
Active, not recruiting NCT04895540 - South Asian Arrhythmogenic Cardiomyopathy Registry